Company Overview and News

25
Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

7h seekingalpha
Allergan is under pressure from activist shareholders and other investors to formulate a clear strategic plan and make more drastic changes to the company.
REGN MYL AMGN AKRX RVNC AGN TEVA EOLS LLY

26
Where Did Major Pharma Short Sellers Go?

2018-07-12 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

29
Your Daily Pharma Scoop: IPO Review - Aptinyx Surges, Kezar Progresses, Neon Slumps

2018-07-11 seekingalpha
Aptinyx (APTX) priced its IPO at $16.00. 6.4M common stock shares were offered. Additional 959,999 shares were on underwriters over-allotment. Gross proceeds initially expected was ~102.4M, but reached $117.8M by the time of closing. The shares opened at $17.40 on June 21. The IPO closed on June 25.
GLENMARK APTX ALPMF AUPH DEPO LLY GSK GLKQY CADILAHC CDLYY 4503 MYL 532321 ALPMY AUP NTGN IMMU BMS 532296 JNJ NVS KZR PFE

1
Trump Tweets Threat to Pfizer but Investors Shrug it Off

2018-07-11 investorplace
Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.
AGN IBB LLY PFE

5
Biogen Is the Right Alzheimer's Stock ... At the Wrong Time | InvestorPlace

2018-07-10 investorplace
On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s.
MS.PRI BIIB AZN MS.PRK MS.PRE MS.PRF MS.PRG LLY MS MS.PRA

16
Week In Review: Suzhou Innovent Files For HK IPO - $500 Million Raise Rumored

2018-07-08 seekingalpha
Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion. Founded in 2011, Innovent has developed a pipeline of 17 biologic drugs with an emphasis on oncology. In 2015, the company formed a historic partnership with Lilly (NYSE: LLY) worth up to $1 billion plus.
SVA BABA RDSMY SCLRF SPH ATNX LLY SNY

14
Your Daily Pharma Scoop: Review Of 3 More Stocks From The Biotech Boom IPO Week (18 - 22 June)

2018-07-04 seekingalpha
Like we said in our previous article on biopharma IPOs, the IPO scene is suddenly buzzing with a lot of excitement. A staggering eight biotech companies were in the process of going public. There are 31 biotech companies that joined the IPO bandwagon this H1, which is more than the number that did so in entire 2012. Even if suddenly it seems that everything is right about the sector, the sector fans certainly know that such booms are usually followed by sharp corrections.
XERS SHPG EIDX AVRO TOCA JUNO NVO LLY BLUE SNY

19
Your Daily Pharma Scoop: Gemphire Zooms, Trevena Succeeds, Arsanis Falters

2018-07-01 seekingalpha
Discussion: Gemphire Therapeutics’ (GEMP) candidate Gemcabene met its Phase 2b primary endpoint in hypertriglyceridemia patients. The company reported significant reduction of up to 47% in patients against 27% for placebo-treated group. This drug candidate is the first oral therapy targeted at ~3.5M patients in the U.S. whose LDL-C or triglyceride level needs to be brought down to avoid further risk of developing acute pancreatitis.
TRVN GEMP BTAI LLY ASNS

259
Stocks To Watch: Tariffs Don't Take Holidays

2018-06-30 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. As usual, a new quarter and the second half of the trading year will begin with a shortened week due to the Independence Day holiday -- a "trading week interruptus," with July 4 landing on Wednesday.
TCBK FBIP TCYSF SIRI ISCA 1128 MT CUKPF FNBG GM.WS.A GM.WS.B GM.WS.C 1928 CBB.PRB NCMI TRBAB AYI SRRK GSKY TRBNW CCL CUK SHERF PSMT MLHR KNSA QCOM FCAU SJMHF GM.WSB PFE SBGI MT RCH SSNLF TM LSXMA NXPI CLPS ZGNX AYI.WI SJMHY MLCO ISCB CCL GM EVOP DIS HCOM F CSTM CMCSA SCHYF CSTM WYNMF LLY MGTX HMC 0880 CBB ITRM BHVN VC RHUHF SIFY 506186 FGEN GLXYENT BHR SNE SCHYY TRCO WYNMY

223
Short Sellers Hike Bets in Major Pharma Stocks

2018-06-27 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

0
LLY / Eli Lilly & Co. SCHEDULE TO-T/A

2018-06-22 sec.gov
Schedule TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LLY

0
LLY / Eli Lilly & Co. SCHEDULE TO-T/A

2018-06-22 sec.gov
Schedule TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LLY

0
ECA2018-109 - Information Regarding the Tender Offer for the Shares of ARMO Biosciences, Inc. (ARMO)

2018-06-19 nasdaqtrader
The tender offer by Eli Lilly and Company (NYSE: LLY) to acquire all of the outstanding common stock of ARMO Biosciences, Inc. (ARMO) is scheduled to expire at 11:59 PM on Thursday, June 21, 2018. Unless terminated, or further extended, the acquisition of ARMO Biosciences, Inc. is anticipated to be completed on a date to be announced. The details are as follows:
ARMO LLY

148
Alzheimer's Disease: A History Of Drug Failures

2018-06-19 seekingalpha
Amyloid is a product of this stress and contributes to it, but so too do many other factors.
AZN BIIB AZN MRK LLY AVXL

0
LLY / Eli Lilly & Co. 11-K

2018-06-18 sec.gov
Document UNITED STATE
LLY

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to LLY / Eli Lilly & Co. on message board site Silicon Investor.

Anything graphite based, CCB, Zen and hopefully much more. For the Psychologically Oriented
Gardening and Especially Tomato Growing Porkbelly futures u0026 political ramifications of Pork Tarrifs
Hemp based foods from Naturally Splendid Enterprises Ltd. Silicon Investor - User Site Discussion - Generally Unmodera
Nancy Pelosi Is Mentally ILL! How Quickly Can Obama Totally Destroy the US?
Digital Ally Inc. - DGLY Dolly Varden
CUSIP: 532457108